Untreated mental health issues, like Treatment-Resistant Depression (TRD), cost U.S. businesses billions annually in lost ...
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...
Some of our patients often tell us they need to experience some undesirable truth first-hand to believe it. Implied is the ...
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...
We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with ...
Ketamine is an old anesthesia drug with psychedelic qualities, and it has been getting a lot of attention for its ability to ...
Highlights: Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025 Phase 3 COMP006 in TRD is on track for ...
A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...